Larimar Therapeutics (LRMR) Operating Leases (2019 - 2026)

Larimar Therapeutics (LRMR) has reported Operating Leases for 8 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases rose 7.72% year-over-year to $3.8 million; the trailing twelve-month figure through Jun 2026 stood at $3.8 million (up 7.72% YoY), and the FY2025 full-year result was $3.0 million, down 26.99% from the prior year.
• Operating Leases rose to $3.8 million in Q2 2026 per LRMR's latest filing, from $3.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $5.2 million in Q1 2022 and bottomed at $3.0 million in Q4 2025.
• Historically, Operating Leases has averaged $4.3 million across 5 years, with a median of $4.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Operating Leases slipped 26.99% in 2025, then climbed 7.72% in 2026.
• Over 5 years, Operating Leases stood at $4.8 million in 2022, then fell by 1.83% to $4.7 million in 2023, then fell by 13.85% to $4.1 million in 2024, then retreated by 26.99% to $3.0 million in 2025, then climbed by 26.74% to $3.8 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $3.8 million, $3.0 million, and $3.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.